Introduction {#s01}
============

Monocytes are short-lived bone marrow--derived immune cells that play an important role in orchestrating inflammation but also promoting tolerance ([@bib29]). These cells are involved in phagocytosis, cytokine secretion, and antigen presentation but are probably best known for their role as a source of tissue macrophages. While not all macrophages are monocyte derived, with many being seeded at birth and maintained during life ([@bib20]), the intestine appears to be particularly reliant on peripheral monocytes as a source of intestinal macrophages ([@bib10], [@bib11]). Although extensive work has been performed on pathways regulating murine monocyte and macrophage function, how these cells are regulated in humans and how such pathways are altered in inflammatory disease are less well understood.

TGFβ is a key multifunctional cytokine that is currently being targeted in a number of human diseases such as cancer and inflammatory disorders ([@bib6]; [@bib5]). An important function of TGFβ is its ability to regulate immunity, particularly T cell responses ([@bib53]). While TGFβ is proposed to drive some effector T cell responses, specifically differentiation of Th9 ([@bib15]; [@bib56]) and Th17 cells ([@bib33]), it is best known for its tolerogenic function ([@bib31]; [@bib48]). For example, TGFβ is important for promoting regulatory T cells ([@bib12]; [@bib16]; [@bib62]; [@bib38]) and blocking differentiation and function of Th1 ([@bib25]; [@bib24]; [@bib37]) and Th2 cells ([@bib23]; [@bib26]; [@bib35]). Indeed, a key role for TGFβ in maintaining T cell homeostasis is shown by the observation that the TGFβ1 knockout mouse dies from CD4^+^ T cell--driven multi-organ inflammation early in life ([@bib50]; [@bib34]). Although much is known about how TGFβ regulates T cell responses, much less is known about how TGFβ regulates innate immune responses, including regulation of monocytes and macrophages, and how such pathways are altered in disease.

TGFβ is expressed ubiquitously, but is always secreted as a latent complex, consisting of the latency-associated peptide (LAP) and active TGFβ moieties ([@bib22]; [@bib42]). Both LAP and active TGFβ are encoded by the *TGFB1* gene, are cleaved from each other intracellularly but remain noncovalently bound, and are secreted with LAP folded around active TGFβ to mask its TGFβ receptor binding sites ([@bib42]). Thus, the function of TGFβ in the regulation of immune responses is controlled by mechanisms that regulate latent TGFβ activation. However, with many of the previous studies being performed in mice, how TGFβ is activated to control human immunity and how this is altered in disease settings are poorly understood.

Here we show that human monocytes and macrophages are key activators of latent TGFβ, with such pathways not present in mice. Mechanistically, this ability to activate TGFβ is dependent on expression of an integrin, αvβ8, with this activation important in dampening pro-inflammatory cytokine production by monocytes. Furthermore, we find that this pathway is highly expressed on human intestinal macrophages, which are reduced in inflammatory bowel disease (IBD) and replaced by incoming pro-inflammatory monocytes/macrophages that lack expression of αvβ8. Our data therefore highlight a new pathway by which human monocyte/macrophage function is regulated, which could be therapeutically targeted to modulate TGFβ-mediated control of innate immunity in inflammatory disease.

Results and discussion {#s02}
======================

Human CD14^+^ monocytes activate TGFβ via expression of the integrin αvβ8 {#s03}
-------------------------------------------------------------------------

Monocytes represent the major mononuclear phagocyte cell population in the periphery with a crucial role in mediating inflammatory responses via regulation of adaptive immunity and maturation into tissue macrophages. Given its major role in controlling immune responses, we hypothesized that TGFβ activation may be important for regulation of monocyte function. We therefore first assessed the ability of CD14^+^ monocytes from human blood to activate TGFβ via co-culture with an active TGFβ reporter cell line ([@bib1]; [Fig. 1 A](#fig1){ref-type="fig"}). As a positive control for the assay, we used U251 cells, which we have previously shown to activate high levels of TGFβ via integrin αvβ8 ([@bib18]). We found that human CD14^+^ monocytes were potent activators of TGFβ ([Fig. 1 B](#fig1){ref-type="fig"}). Surprisingly, this ability was not present on murine monocytes, which did not activate any TGFβ above the baseline of reporter cells alone ([Fig. 1 B](#fig1){ref-type="fig"}), suggesting that this pathway is specific to humans. The failure to detect TGFβ activation by mouse monocytes was not due to an inability of the reporter cells to respond to murine TGFβ, as a near identical response was observed in the presence of recombinant active mouse and human TGFβ1 (Fig. S1 A). Additionally, the lack of TGFβ activation by mouse monocytes could not be explained by their inability to produce latent TGFβ, which was shown to be equivalent to human monocytes (Fig. S1 B).

![**Human peripheral blood monocytes activate TGFβ in an integrin αvβ8--dependent manner. (A)** Illustration of TGFβ activation assay whereby cells of interest are co-cultured with active TGFβ reporter cells ([@bib1]) expressing a TGFβ-inducible promoter fused to luciferase. **(B)** Human CD14^+^ blood monocytes (*n* = 8) and murine splenic Ly6c^+^ monocytes (*n* = 3, each data point representing two pooled mice) were isolated and co-cultured with active TGFβ reporter cells overnight, before measuring luciferase activity (active TGFβ concentration calculated from standard curve). Reporter cells alone were used as a negative control (*n* = 8), and U251 cells (*n* = 8; [@bib18]) were used as a positive control. **(C)** Healthy human PBMCs were analyzed by flow cytometry. Following gating on single, live cells, integrin β8 expression was identified on lymphocyte populations (CD3 for T cells, CD19 for B cells, and CD56 for NK cells), DCs (lineage-negative \[CD3, CD14, CD15, CD16, CD19, CD20, and CD56\] HLA-DR^+^ CD11c^+^ with subsets identified by CD1c and CD141 staining), and monocytes (HLA-DR^+^, CD14^+^, and CD16^+^) following gating on forward and side scatter (*n* = 4--19). **(D)** RNA from murine spleen Ly6c^hi^ monocytes (lineage-negative \[TCRβ, NK1.1, B220, CD19, Ter119, Ly6G, and Siglec F\], CD11b^+^, Ly6c^+^) was analyzed for *Itgb8* expression by real-time PCR, normalizing to the housekeeping gene *Hprt* (*n* = 6, each from two pooled mice). Bone marrow--derived DCs were used as a positive control. **(E)** TGFβ activation of human CD14^+^ monocytes (*n* = 6) was measured in the presence of an isotype control antibody or an integrin β8 blocking antibody. Bars show mean and SD. n.s., not significant; n.d., not detected; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001; P values were determined by Kruskal--Wallis with Dunn's multiple comparisons test (B and C) and Wilcoxon matched-pairs signed rank test (E).](JEM_20171491_Fig1){#fig1}

Next, we looked to identify mechanisms responsible for the ability of human CD14^+^ monocytes to activate TGFβ. As we and others have recently shown that an integrin, αvβ8, is a key activator of TGFβ in the murine immune system ([@bib36]; [@bib54]; [@bib2]; [@bib46]; [@bib58], [@bib59], [@bib60]), we assessed expression of integrin αvβ8 on human peripheral immune cells by flow cytometry. As recently described ([@bib18]), integrin αvβ8 was expressed by CD1c^+^ but not CD141^+^ dendritic cells (DCs; [Fig. 1 C](#fig1){ref-type="fig"}). However, integrin αvβ8 was most highly expressed by blood monocytes, with ∼70% of these cells expressing the integrin ([Fig. 1 C](#fig1){ref-type="fig"}). In contrast, minimal expression of integrin αvβ8 was observed on lymphocyte populations ([Fig. 1 C](#fig1){ref-type="fig"}). In agreement with their lack of ability to activate TGFβ ([Fig. 1 B](#fig1){ref-type="fig"}), expression of integrin αvβ8 on murine Ly6c^hi^ monocytes isolated from spleen was undetectable, in contrast to expression on murine DCs ([Fig. 1 D](#fig1){ref-type="fig"}), which we have previously shown use integrin αvβ8 to activate TGFβ ([@bib54]; [@bib58]).

To directly test whether expression of integrin αvβ8 is responsible for the ability of human blood monocytes to activate TGFβ, we used a recently described integrin β8 functional blocking antibody ([@bib18]). Treatment of monocytes with the integrin-blocking antibody almost completely ablated their ability to activate TGFβ ([Fig. 1 E](#fig1){ref-type="fig"}). These results show that human but not murine monocytes can activate high levels of the cytokine TGFβ, which is dependent on expression of the integrin αvβ8.

Previous results have shown that both mouse and human DCs can activate TGFβ via integrin αvβ8, suggesting some level of conservation in this pathway ([@bib58]; [@bib18]). However, our data now suggest that there is a new cellular pathway that regulates TGFβ activity in the human immune system, via monocyte expression of integrin αvβ8. Although our data show that murine monocytes are not capable of activating TGFβ, we cannot rule out that, in some biological contexts such as infection or inflammation, certain mouse monocyte subsets could activate TGFβ via integrin αvβ8--dependent or --independent pathways. However, the species-specific differences observed are in agreement with studies suggesting significant gene expression ([@bib27]) and functional ([@bib19]) differences between human and mouse monocytes. Given the great interest in targeting TGFβ function in human diseases such as cancer and inflammation ([@bib6]), it is crucial to understand human-specific pathways controlling the function of TGFβ.

All human monocyte subsets express integrin αvβ8, but only CD14^+^ classical and intermediate monocytes activate TGFβ {#s04}
---------------------------------------------------------------------------------------------------------------------

In humans, distinct monocyte subsets can be identified based on expression of the surface proteins CD14 and CD16 ([@bib63]; [@bib13]). Thus, CD14^+^CD16^−^ classical monocytes represent 70--80% of blood monocytes, with CD14^+^CD16^+^ intermediate and CD14^−^CD16^+^ nonclassical monocyte subsets also existing, with recent data suggesting that human monocytes differentiate in a sequential manner from classical to intermediate and nonclassical monocytes ([@bib47]). The different subsets are proposed to have distinct functions; for example, classical monocytes can produce pro-inflammatory cytokines and migrate to tissue sites where they differentiate into macrophages ([@bib17]; [@bib21]), whereas nonclassical CD16^+^ monocytes are thought to patrol the endothelium and be involved in anti-viral responses ([@bib7]; [@bib14]). Therefore, we next determined whether there was heterogeneity in the ability of different human monocyte subsets to activate TGFβ.

We first assessed integrin αvβ8 expression levels on different human monocyte subsets. Expression was similarly high on classical, intermediate, and nonclassical monocytes, with a slightly but significantly higher expression present on intermediate monocytes ([Fig. 2, A and B](#fig2){ref-type="fig"}), suggesting that all human monocyte subsets would be capable of activating TGFβ. However, although classical monocytes activated high levels of TGFβ, which was inhibited by an integrin αvβ8 functional blocking antibody, activation was almost completely absent by nonclassical monocytes, with intermediate levels of TGFβ activation observed by the intermediate monocyte subset ([Fig. 2, C and D](#fig2){ref-type="fig"}). Differences in TGFβ activation between monocytes could not be explained by differences in their ability to produce latent TGFβ, with all subsets expressing equivalent levels of latent TGFβ1 (Fig. S1 C). These data suggest that expression of integrin αvβ8 promotes TGFβ activation by classical monocytes, but that expression of the integrin is not sufficient to activate TGFβ in all monocyte subsets.

![**The CD14^+^ classical monocyte subset activates high levels of TGFβ via integrin αvβ8 and MMP14. (A and B)** PBMCs were gated on single, live HLA-DR^+^ cells, then as CD14^+^CD16^−^ classical monocytes (green gate), CD14^+^CD16^+^ intermediate monocytes (red gate), and CD14^−^CD16^+^ nonclassical monocytes (blue gate). Levels of integrin β8 were measured on each subset (colored histogram, integrin β8 antibody; gray histogram, isotype control). Representative flow cytometry plots (A) and quantification of integrin β8 levels (B); *n* = 19 healthy donors. **(C and D)** Monocyte subsets were isolated by flow cytometry sorting and co-cultured overnight with a TGFβ reporter cell line (C; *n* = 10--13 donors) in the presence of an isotype or anti--integrin β8 antibody (D; *n* = 3--6 donors). Bars show mean and SD. **(E and F)** MMP14 expression was measured by real-time PCR, normalizing to the housekeeping gene *B2M* (E; *n* ≥ 5 for each subset) and flow cytometry (F; *n* = 8 for each subset) in monocyte subsets. Bars show mean and SD. **(G)** Active TGFβ production by CD14^+^ monocytes in the presence of an isotype control, integrin β8 blocking, or MMP14 blocking antibody (*n* = 6 donors). Bars show mean and SD. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001; n.s., not significant; P values were determined by Friedman test with Dunn's multiple comparisons post-test (B, F, and G), Wilcoxon matched-pairs signed rank test (D), and Kruskal--Wallis with Dunn's multiple comparisons post-test (C and E).](JEM_20171491_Fig2){#fig2}

To determine mechanisms that promote differential TGFβ activation by monocyte subsets, despite all expressing high integrin αvβ8 levels, we focused on the expression of matrix metalloproteinase 14 (MMP14, also known as MT1-MMP), which has been suggested to synergize with integrin αvβ8 to promote TGFβ activation in some cells ([@bib41]). Expression levels of MMP14 correlated with the ability of monocyte subsets to activate TGFβ via integrin αvβ8, with the highest levels seen in classical monocytes, and almost 10-fold lower levels in nonclassical monocytes ([Fig. 2, E and F](#fig2){ref-type="fig"}). To more directly assess the role for MMP14 in the ability of monocytes to activate TGFβ, we analyzed the ability of CD14^+^ monocytes to activate TGFβ in the presence or absence of an MMP14-blocking antibody. Inhibition of MMP14 resulted in a significant decrease in TGFβ activation, to similar levels observed in the presence of an integrin β8--blocking antibody ([Fig. 2 G](#fig2){ref-type="fig"}). Thus, overall, these data show an association between the expression of MMP14 and the ability of monocyte subsets to activate TGFβ, with classical monocytes requiring both integrin αvβ8 and MMP14 activity to promote TGFβ activation. Activation of TGFβ by other integrins, such as αvβ6, does not require MMP14 ([@bib43]), and the ability of integrin αvβ8 to activate TGFβ in some cell types---for example, regulatory T cells ([@bib51])---appears to be MMP14-independent. Here, our data suggest that expression of MMP14 at high levels on CD14^+^ monocytes likely cooperates with integrin αvβ8 to activate TGFβ via its enzymatic activity, a process that is lacking in other monocyte subsets.

Integrin αvβ8--mediated TGFβ activation dampens pro-inflammatory cytokine production by human blood classical monocytes {#s05}
-----------------------------------------------------------------------------------------------------------------------

We next investigated the functional importance of TGFβ activation by human monocytes, focusing on CD14^+^ classical monocytes, given that they activate the highest levels of TGFβ via integrin αvβ8 and MMP14. In support of a potential autocrine function for TGFβ activation by classical monocytes, these cells express high levels of the TGFβ receptor ([Fig. 3 A](#fig3){ref-type="fig"}), which is functionally active, as shown by phosphorylation of the TGFβ signaling protein Smad2/3 in response to active TGFβ ([Fig. 3 B](#fig3){ref-type="fig"}).

![**Integrin αvβ8--mediated TGFβ activation reduces monocyte TNFα production in response to LPS and is down-regulated upon differentiation to pro-inflammatory macrophages. (A)** TGFβ receptor chain II (TGFβRII, red histogram) levels were assessed by flow cytometry on CD14^+^ monocytes (isotype control, gray histogram; graph shows cumulative data of *n* = 7 donors). **(B)** Levels of the TGFβ signaling molecule pSmad2/3 were measured in CD14^+^ classical monocytes (*n* = 3) after treatment of PBMCs with 5 ng/ml TGFβ for 30 min (isotype control shown in gray). Representative flow cytometry plots are displayed. **(C and D)** TNFα production by CD14^+^ monocytes was measured by intracellular flow cytometry, following PBMC culture overnight in the presence of an isotype control, anti-TGFβ, or anti--integrin β8 blocking antibody followed by activation with 10 ng/ml LPS for 4 h in the presence of a protein transport inhibitor; C shows representative flow cytometry plots; D shows cumulative data (*n* = 18). **(E)** TNFα production by CD14^+^ monocytes as in C and D, with addition of 5 ng/ml active TGFβ in the presence of anti--integrin β8 antibody (*n* = 9). **(F and G)** CD14^+^ monocytes were cultured for 6 d with GM-CSF or M-CSF to differentiate to macrophages and integrin β8 expression measured by flow cytometry; F displays representative flow cytometry plots for macrophage expression of integrin β8; G shows pooled data for monocyte and macrophage expression of integrin β8 from 10--19 donors. **(H)** Monocytes and MDMs were co-cultured overnight with active TGFβ reporter cells (*n* = 6--8 donors). \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*\*, P \< 0.0001, n.s., not significant; P values were determined by Friedman test with Dunn's multiple comparisons post-test (D and E) or Kruskal--Wallis with Dunn's multiple comparisons post-test (G and H).](JEM_20171491_Fig3){#fig3}

As monocytes are key, short-lived innate effector cells that can produce pro-inflammatory cytokines in response to pathogen challenge, and TGFβ can regulate cytokine production in other immune cells such as T cells ([@bib31]), we hypothesized that integrin αvβ8--mediated TGFβ activation may modulate the ability of monocytes to produce cytokines. To test this possibility, cells were cultured in the presence of blocking antibodies against TGFβ or integrin αvβ8 and then stimulated with LPS. In the presence of a TGFβ-blocking antibody, monocytes produced significantly increased levels of the pro-inflammatory cytokine TNFα ([Fig. 3, C and D](#fig3){ref-type="fig"}). Importantly, blockade of integrin αvβ8 yielded a similar increase in TNFα production by monocytes ([Fig. 3, C and D](#fig3){ref-type="fig"}), with this increase significantly reduced by addition of active TGFβ ([Fig. 3 E](#fig3){ref-type="fig"}).

Thus, these results indicate that integrin-mediated TGFβ activation normally functions to restrict CD14^+^ monocyte pro-inflammatory cytokine secretion. Such a function may act to potentiate over-activation of monocytes to prevent excessive inflammation. However, the functional importance of such a feedback loop requires further attention, especially in the light of recent data suggesting that, at least in the mouse, TNFα is an important survival factor for monocytes in steady state and inflammation ([@bib57]).

Integrin αvβ8--mediated TGFβ activation is up-regulated on anti-inflammatory macrophages and down-regulated on pro-inflammatory macrophages {#s06}
-------------------------------------------------------------------------------------------------------------------------------------------

An important function of monocytes is the migration from the bone marrow and peripheral blood to tissue sites where they can differentiate into macrophages during homeostasis and inflammation ([@bib20]). We therefore tested whether the ability of monocytes to activate TGFβ was altered after differentiation into macrophages. To this end, we differentiated monocytes to macrophages in vitro, using the cytokines GM-CSF and M-CSF, which have been shown previously to give rise to pro-inflammatory and anti-inflammatory phenotypes, respectively ([@bib44]). Indeed, in agreement with previous findings ([@bib3]; [@bib4]), we showed that GM-CSF--derived macrophages produced lower levels of IL-10 and were less phagocytic than M-CSF--derived macrophages (Fig. S2, A and B).

We found that pro-inflammatory GM-CSF--differentiated macrophages down-regulated expression of integrin αvβ8 compared with CD14^+^ monocytes, whereas monocytes differentiated to anti-inflammatory macrophages in the presence of M-CSF expressed high levels of integrin αvβ8, displaying close to 100% expression ([Fig. 3, F and G](#fig3){ref-type="fig"}). Additional polarization of GM-CSF--treated cells with IFN-γ and M-CSF--treated cells with IL-4, shown to further promote pro- and anti-inflammatory phenotypes, respectively ([@bib44]), showed similar changes in integrin αvβ8 expression levels to GM-CSF and M-CSF treatment alone (Fig. S2, C--E). Expression of MMP14 was uniformly higher on both GM-CSF-- and M-CSF--differentiated macrophages versus monocytes (Fig. S2 F), suggesting that signals received during the differentiation caused up-regulation of MMP14 expression.

These results suggest that macrophage populations may have differential abilities to activate TGFβ. Indeed, M-CSF--differentiated macrophages activated similar levels of TGFβ to CD14^+^ monocytes, whereas GM-CSF--differentiated macrophages showed a reduced ability to activate TGFβ ([Fig. 3 H](#fig3){ref-type="fig"}). Thus, our data show that anti-inflammatory macrophages are able to activate TGFβ, whereas this ability is down-regulated on more pro-inflammatory macrophage populations. Indeed, these results fit with previous findings suggesting that TGFβ is an important "M2" anti-inflammatory macrophage marker ([@bib28]).

Human intestinal macrophages express high levels of integrin αvβ8 and are reduced in patients with IBD {#s07}
------------------------------------------------------------------------------------------------------

While in vitro--derived macrophages are a useful model, macrophages exist in multiple different phenotypes in vivo ([@bib61]). In healthy tissue, anti-inflammatory macrophages capable of maintaining homeostasis are common, whereas a switch to pro-inflammatory monocytes/macrophages occurs during infection and inflammation ([@bib55]). Given the proposed importance of tolerogenic macrophages in the intestine and the fact that intestinal macrophages derive predominantly from blood monocytes ([@bib11]), coupled with data suggesting that TGFβ is a crucial cytokine in maintenance of immune homeostasis in the gut ([@bib32]; [@bib31]), we next assessed expression of integrin αvβ8 on human intestinal tissue macrophages. We found that intestinal macrophages, identified by gating on CD45^+^ lineage-negative, HLA-DR^+^CD14^+^CD64^+^ cells (Fig. S3 A), expressed high levels of integrin αvβ8 compared with CD64^−^ cells ([Fig. 4 A](#fig4){ref-type="fig"}). These integrin αvβ8^+^ intestinal macrophages also express CD163 and CD206 ([Fig. 4 B](#fig4){ref-type="fig"}), which have been proposed as markers of anti-inflammatory intestinal macrophages ([@bib10]). Notably, murine intestinal macrophages, like murine monocytes, do not express integrin αvβ8 (Fig. S3 B), again highlighting an important species-specific difference in pathways that activate TGFβ.

![**Integrin αvβ8 is highly expressed on intestinal macrophages and is decreased in patients with IBD. (A)** Integrin β8 levels were analyzed by flow cytometry on human colonic monocyte/macrophage populations, gated as single, live, CD45^+^, lineage-negative (CD3, CD15, CD19, CD20, and CD56), HLA-DR^+^CD14^+^CD64^+^ cells. Expression of integrin αvβ8 was compared with equivalent CD14^−^CD64^−^ cells (*n* = 9). **(B)** Integrin β8^+^ monocytes/macrophages were analyzed for expression of the tissue macrophage markers CD163 and CD206 by flow cytometry (representative image from *n* = 9 donors). **(C and D)** Human monocyte/macrophage populations, identified as described in A, were gated for expression of the monocyte marker CCR2 and expression of integrin β8 on monocytes (CD14^+^CCR2^+^) and macrophages (CD14^+^CCR2^−^) analyzed. Representative flow cytometry plots (C) and cumulative data (D) from 11 donors are depicted. SSC-H, side scatter height. **(E)** Monocyte and macrophage populations in the intestinal tissue of healthy versus inflamed IBD patients were analyzed by flow cytometry (gated as described in C and D) with histograms showing levels of HLA-DR expression on monocytes (purple) and macrophages (blue) in healthy tissue compared with IBD. Representative plots shown, with F showing cumulative data for CCR2^+^ monocyte and CCR2^--^ macrophage levels from 11--12 healthy or IBD donors. **(G and H)** Expression levels of integrin αvβ8 were measured on monocyte/macrophage populations from healthy patients and patients with IBD. Representative histograms (G) and cumulative data (H) from 11 healthy and IBD donors are depicted. Bars show mean and SD. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; P values were determined by Wilcoxon matched-pairs signed rank test (A and D) or Mann--Whitney (F and H).](JEM_20171491_Fig4){#fig4}

We also gated cells on the basis of CCR2, with CCR2^+^ cells proposed to represent recently emigrated intestinal monocytes that are yet to differentiate to macrophages ([@bib9]). Such cells are a minor fraction of total intestinal HLA-DR^+^CD14^+^CD64^+^ cells in the healthy human intestine ([Fig. 4 C](#fig4){ref-type="fig"}) and display low forward scatter/side scatter levels compared with CCR2^--^ cells (Fig. S3 C), further supporting that such cells represent a monocyte/immature macrophage population. We found that both CD14^+^CCR2^+^ monocyte and CD14^+^CCR2^−^ macrophage populations in the intestine expressed high integrin αvβ8 levels, with significantly higher levels found on tissue macrophages ([Fig. 4, C and D](#fig4){ref-type="fig"}). Thus, together these data suggest that integrin αvβ8 is highly expressed on monocytes that enter the healthy intestine, and remains high as cells develop into macrophages.

Having established that integrin αvβ8 is conserved between human peripheral CD14^+^ monocytes and intestinal macrophages in the healthy intestine, we next addressed whether the pathway was altered in individuals with IBD. We observed a shift in the balance of monocytes and macrophages in the inflamed versus healthy intestine, with a significant increase in a CD14^hi^ HLA-DR^dim^ CCR2^+^ population ([Fig. 4, E and F](#fig4){ref-type="fig"}), proposed from previous work in mouse and humans to represent an inflammatory monocyte population ([@bib30]; [@bib10]; [@bib45]; [@bib52]; [@bib39]). This influx of monocytes substantially reduces the proportion of tissue macrophages present ([Fig. 4, E and F](#fig4){ref-type="fig"}). Importantly, whereas both the monocyte population and tissue macrophages display clear expression of integrin αvβ8 in the healthy intestine, expression of the integrin is significantly down-regulated on inflammatory monocytes and remaining tissue macrophages in IBD ([Fig. 4, G and H](#fig4){ref-type="fig"}). MMP14 expression was also present in both intestinal monocytes and macrophages in healthy tissue, but was not altered in cells from patients with IBD (Fig. S3 D). When patients were stratified into those with Crohn's disease or ulcerative colitis, significant reductions in monocyte and macrophage integrin β8 expression were observed in both disorders (Fig. S3, E and F). Thus, our results show that integrin αvβ8 is highly expressed on monocyte/macrophage populations in the steady-state intestine, but during inflammation, populations of integrin αvβ8--negative monocytes predominate.

Previous data have shown that, although levels of total latent TGFβ are increased in the intestine in IBD ([@bib8]), TGFβ signaling is in fact decreased ([@bib40]). This apparently paradoxical finding was proposed to be due to enhanced expression of the TGFβ signaling inhibitor Smad7 in IBD, with targeting of Smad7 promoting enhanced TGFβ signaling ([@bib40]). Our data now suggest that a reduced ability to activate TGFβ in the inflamed intestine, via down-regulation of integrin αvβ8--expressing monocytes/macrophages, may contribute to the reduced ability to trigger TGFβ signaling in the inflamed intestine. Together with our data ([Fig. 3, C--E](#fig3){ref-type="fig"}) showing that integrin αvβ8 expression on monocytes is required for the dampening of pro-inflammatory cytokine expression, our work suggests that down-regulation of this autocrine regulatory pathway in inflammatory monocyte/macrophage populations may promote inflammation. Additionally, as recent work in mouse models has suggested that TGFβ can promote intestinal macrophage differentiation in the steady state ([@bib49]), reduction of TGFβ activation pathways during inflammation may help explain the reduced proportions of intestinal macrophage populations observed in IBD patients.

To conclude, we have demonstrated that human but not murine monocytes and macrophages are specialized to activate TGFβ via expression of integrin αvβ8, which plays a regulatory role in dampening LPS-induced pro-inflammatory cytokine responses. This pathway is present on intestinal monocyte/macrophage populations during health, but is dysregulated during intestinal inflammation, suggesting that the pathway may represent a key immune regulatory mechanism in inflammation. Thus, promoting monocyte/macrophage ability to activate TGFβ via integrin αvβ8 may be a valid therapeutic strategy in inflammatory disorders such as IBD. To achieve this, it will be important in the future to determine signals that lead to the down-regulation of integrin αvβ8 during inflammation, which could then be targeted to promote the pathway. Targeting integrin αvβ8 (via small molecule inhibitors or blocking antibodies) is also attractive in the treatment in fibrosis (given the pro-fibrotic properties of TGFβ) and cancer (given the anti-inflammatory properties of TGFβ in the tumor microenvironment). However, our new data now highlight previously unappreciated cell types that will also be targeted by blocking integrin αvβ8 in humans, which will need to be considered in future therapeutic strategies.

Materials and methods {#s08}
=====================

Samples and ethics {#s09}
------------------

Human samples were obtained according to the principles expressed in the Declaration of Helsinki and under local ethical guidelines, and approved by the North West National Ethics Service (reference no. 15/NW/0007). Intestinal tissue samples were obtained via the Central Manchester University Hospitals National Health Service (NHS) Foundation Trust Biobank from patients undergoing surgery or endoscopy for chronically active Crohn's disease or ulcerative colitis. The diagnosis of IBD was confirmed by established clinical, radiological, and histological criteria. Specimens were collected from healthy areas of colorectal cancer patients or patients undergoing endoscopy as noninflammatory controls. All patients provided written, informed consent for the collection of tissue samples and subsequent analysis. Healthy blood was obtained from donors recruited locally (according to the University of Manchester ethics and guidelines) or from leukocyte cones sourced from the blood bank (National Blood Service, Manchester, UK). Patient demographic and clinical information is listed in [Table 1](#tbl1){ref-type="table"}.

###### Demographic and clinical data for patients who donated intestinal samples analyzed in the study

  Sample type                     Gender   Tissue   Age (yr)                                  Diagnosis                                IBD medication
  ------------------------------- -------- -------- ----------------------------------------- ---------------------------------------- --------------------------
  **Healthy (non-IBD) samples**                                                                                                        
  Resections                      Male     Colon    73                                        Sigmoid colon cancer                     N/A
  Male                            Colon    73       Concurrent bladder and rectal cancer      N/A                                      
  Female                          Colon    74       Sigmoid adenocarcinoma                    N/A                                      
  Male                            Colon    75       Colorectal cancer with liver metastases   N/A                                      
  Female                          Colon    63       Caecal tumor and bladder tumor            N/A                                      
  Female                          Colon    73       Adenocarcinoma                            N/A                                      
  Male                            Colon    64       Adenocarcinoma                            N/A                                      
  Male                            Colon    64       Adenocarcinoma                            N/A                                      
  Female                          Colon    51       Colon cancer with metastases              N/A                                      
  Male                            Colon    40       Rectal carcinoma with metastases          N/A                                      
  Male                            Rectum   67       Rectal carcinoma                          N/A                                      
  Female                          Colon    57       Colon cancer with metastases              N/A                                      
  Female                          Colon    61       Colonic polyp                             N/A                                      
  Biopsies                        Male     Colon    46                                        Healthy (screen for cancer)              N/A
  Female                          Colon    61       Healthy (screen for cancer)               N/A                                      
  Male                            Colon    79       Healthy (screen for cancer)               N/A                                      
  **IBD patients**                                                                                                                     
  Resections                      Female   Colon    31                                        Active Crohn's disease                   Azathioprine
  Female                          Colon    21       Active Crohn's disease                    Vedolizumab, prednisolone                
  Male                            Colon    25       Active Crohn's disease                    Infliximab, methotrexate                 
  Female                          Colon    47       Active Crohn\'s disease                   Prednisolone, simethicone                
  Female                          Colon    59       Active Crohn's disease                    Azathioprine, adalimumab, methotrexate   
  Male                            Colon    51       Active ulcerative colitis                 Adalimumab                               
  Male                            Colon    25       Active ulcerative colitis                 Azathioprine, mesalazine                 
  Biopsies                        Male     Rectum   25                                        Active Crohn's disease                   Adalimumab, methotrexate
  Female                          Colon    23       Active Crohn's disease                    Infliximab                               
  Male                            Rectum   17       Active ulcerative colitis                 Infliximab                               
  Male                            Rectum   57       Active ulcerative colitis                 Prednisone, omeprazole, mesalazine       

N/A, not applicable.

Peripheral blood mononuclear cells (PBMCs) and monocyte isolation {#s10}
-----------------------------------------------------------------

PBMCs were separated from healthy donor blood by layering over Ficoll Paque Plus (GE Healthcare) before centrifugation. Monocytes were isolated from PBMCs by magnetic bead separation using CD14 microbeads (Miltenyi Biotech), as per the manufacturer's instructions. Monocyte purity was consistently \>95%. Monocyte subsets were isolated by pre-enrichment using a Pan-Monocyte Isolation Kit or HLA-DR bead isolation kit (both from Miltenyi Biotech) followed by sorting by flow cytometry based on CD14 and CD16 expression.

Monocyte-derived macrophages (MDMs) {#s11}
-----------------------------------

MDMs were differentiated in RPMI plus [l]{.smallcaps}-glutamine (Sigma-Aldrich) with 10% FCS (Life Technologies, Thermo Fisher Scientific) and 1% penicillin/streptomycin (Sigma-Aldrich) in 12-well plates at 0.5 × 10^6^/ml for 6--7 d. Recombinant human GM-CSF or M-CSF (Peprotech) was added at a concentration of 50 ng/ml. Fresh media and cytokines were added on day 3.

Murine monocyte isolation {#s12}
-------------------------

Monocytes were isolated from the spleens of wild-type C57BL/6 mice. Briefly, spleens were pressed through a 40-µM cell strainer and washed with RPMI. Red cells were lysed using red cell lysis buffer (Sigma-Aldrich), and cells pre-enriched using a Monocyte Isolation Kit (BM; Miltenyi Biotech) as per the manufacturer's instructions. Fc receptor block of enriched cells, using TruStain FcX (BioLegend), was performed, followed by staining and sorting of cells using the FACS Aria (BD Biosciences) via gating on lineage-negative (TCRβ, NK1.1, B220, CD19, Ter119, Ly6G, and Siglec F), CD11b^+^, Ly6c^+^ monocytes. 7-AAD (BioLegend) was used to discriminate dead cells (see Table S1 for antibody details).

Isolation of lamina propria mononuclear cells (LPMCs) {#s13}
-----------------------------------------------------

LPMCs were isolated from tissue by first removing muscle and fat and then washing in HBSS, penicillin-streptomycin, G418 (Melford), and 1 mM dithiothreitol (Sigma-Aldrich). Tissue was then washed three times in HBSS, penicillin-streptomycin, G418, and 1 mM EDTA (Sigma-Aldrich) to remove epithelial cells. The tissue was then cut into small pieces and digested in Collagenase A (Roche) in 10% RPMI, penicillin-streptomycin, and G418 with 60 U/ml DNase I (Roche) for 1 h in a shaking incubator at 37°C. After this time, the tissue was filtered through a 40-µM filter, and cells were analyzed by flow cytometry.

Flow cytometry surface staining {#s14}
-------------------------------

PBMCs, monocytes, MDMs, and LPMCs were stained in PBS with 1% FCS and 0.1% sodium azide (FACS buffer) by first preincubating in 2% mouse serum (Invitrogen), followed by staining for 20 min on ice (see Table S1 for details of all antibodies used). Cells were analyzed using a LSR Fortessa cytometer (BD Biosciences). Data were analyzed using Flowjo v10.1 (TreeStar).

Phosphorylated (p)Smad2/3 intracellular staining {#s15}
------------------------------------------------

For pSmad2/3 staining, 100 µl of whole blood (100 µl/test) was either untreated or stimulated with TGFβ (Peprotech) for 30 min and then fixed by adding 1 ml of prewarmed 1X Lyse/Fix Buffer (BD Biosciences). Surface staining was performed for 60 min at room temperature using HLA-DR, CD14, and CD16, followed by washing and permeabilization using ice-cold Perm buffer III (BD Biosciences) for 30 min on ice. Following permeabilization, intracellular staining was performed using pSmad2/3 antibody (BD Biosciences) for 60 min at room temperature. Samples were washed in FACS buffer and acquired on the LSR Fortessa flow cytometer on the same day.

Monocyte intracellular cytokine staining {#s16}
----------------------------------------

Isolated PBMCs were cultured at 2 × 10^6^/ml in 10% RPMI in a 96-well flat-bottomed plate overnight in the presence of mouse IgG (40 µg/ml; Sigma-Aldrich) and isotype control antibody (40 µg/ml; clone MOPC-21; BioXCell), TGFβ blocking antibody (40 µg/ml; clone 1D11; BioXCell), or integrin β8 blocking antibody (20 µg/ml; clone ADWA16; [@bib18]). In some experiments, 5 ng/ml active TGFβ (Peprotech) was also added to cultures overnight. Cells were then stimulated with 10 ng/ml LPS (L4391; Sigma-Aldrich) for 4 h in the presence of GolgiPlug protein transport inhibitor (BD Biosciences). Following stimulation, cells were stained with lineage markers (CD3, CD15, CD19, CD20, and CD56), HLA-DR, CD14, and CD16, permeabilized with 0.5% saponin (Sigma-Aldrich), and then stained for intracellular TNFα. Cells were washed in saponin, resuspended in FACS buffer, and acquired on the LSR Fortessa on the same day.

TGFβ activation assay {#s17}
---------------------

Transformed mink lung epithelial cells transfected with a plasmid containing firefly luciferase complementary DNA downstream of a TGFβ-sensitive promoter (a gift from D. Rifkin, New York University, New York, NY; [@bib1]) were seeded in 96-well flat-bottomed plates in DMEM containing 10% FCS for at least 3 h. Monocytes or MDMs were added in the same medium in the presence of mouse IgG (40 µg/ml; Sigma-Aldrich) and isotype control antibody (40 µg/ml; clone MOPC-21; BioXCell), TGFβ blocking antibody (40 µg/ml; clone 1D11; BioXCell), integrin β8 blocking antibody (20 µg/ml; clone ADWA16) as described previously ([@bib58]; [@bib18]), or MMP14 blocking antibody (MAB3328; Merck Millipore). Cells were co-cultured for 16--20 h, and luciferase was then detected using the Luciferase Assay System (Promega) using an Infinite M200 Pro instrument (Tecan). A standard curve of active TGFβ (Peprotech) was generated and used to calculate levels of active TGFβ from luminescence intensity observed. TGFβ activity was determined as sample values with anti-TGFβ antibody background values subtracted. For comparison of mouse and human active TGFβ, recombinant proteins were purchased from BioLegend.

Real-time PCR {#s18}
-------------

RNA was isolated using RNeasy Mini or Micro kits (Qiagen). cDNA was synthesized using a High-Capacity RNA-to-cDNA kit (Applied Biosystems), and PCR was performed with Taqman Universal Mastermix II (Applied Biosystems/Thermo Fisher Scientific) on a QuantStudio 12K Flex instrument (Applied Biosystems). Primers used were as follows (all from Applied Biosystems): mouse *Itgb8* primers (Mm00623991_m1), mouse *Tgfb1* primers (Mm01178820_m1), human *MMP14* primers (Hs01037003_g1), and human *TGFB1* primers (Hs00998133_m1). Expression levels were calculated relative to the control genes *B2M* (Hs00984230_m1) for human and *Hprt* (Mm01545399_m1) for mouse.

IL-10 ELISA {#s19}
-----------

96-well Nunc Maxisorp plates (eBioscience) were coated with anti--IL-10 capture antibody overnight (eBioscience). Following a blocking step with ELISA/ELISPOT diluent (eBioscience), supernatants from day 7 MDM cultures were incubated in wells followed by addition of a biotinylated IL-10 detection antibody (eBioscience). Avidin-HRP (eBioscience) was added and 3,3′,5,5′-tetramethylbenzidine (TMB) solution was used to detect peroxidase activity, followed by TMB stop solution (BioLegend). Absorbance readings were measured using an Infinite M200 Pro plate reader (Tecan).

Phagocytosis assay {#s20}
------------------

On day 7 of culture, MDM supernatants were removed and replaced with fresh media. pHrodo Red *E. Coli* Bioparticles Conjugate for Phagocytosis (Life Technologies/Thermo Fisher Scientific) was added and incubated for 1 h, with pretreatment of cells with 5 µg/ml of Cytochalasin D (Sigma-Aldrich) for 30 min before addition of pHrodo particles used as a negative control. Cells were washed, removed by gentle scraping, fixed in 2% formaldehyde (Sigma-Aldrich), and analyzed by flow cytometry using an LSR II flow cytometer (BD Biosciences).

Statistical analysis {#s21}
--------------------

Data were analyzed using GraphPad Prism version 7.0 for Mac. Statistical differences were tested as described in figure legends. Data are displayed as mean or mean and SD, as described in the figure legends.

Online supplemental material {#s22}
----------------------------

Fig. S1 shows active TGFβ reporter cell responses to mouse and human TGFβ1, and expression of TGFβ1 by human and mouse monocytes, and human monocyte subsets. Fig. S2 shows functional characterization of different MDM models and integrin αvβ8 and MMP14 expression on MDMs differentiated with various cytokines. Fig. S3 shows the gating strategy for monocyte/macrophage populations in human intestinal tissue, expression of integrin β8 on murine intestinal macrophages, MMP14 expression by monocytes and macrophages in health versus IBD, and expression of integrin β8 in Crohn's disease and ulcerative colitis patients. Table S1 is a list of monoclonal antibodies used in the study.

Supplementary Material
======================

###### Supplemental Materials (PDF)

###### Table S1 (Excel file)
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